Evidence map›Paper›PMID 31379005›Full record

ArticleMagnetic resonance in chemistry : MRC2021

NMR characterization of rearranged staurosporine aglycone analogues from the marine sponge Damiria sp.

Trong D Tran, Laura K Cartner, Heidi R Bokesch, Curtis J Henrich, Xin W Wang, Chulabhorn Mahidol, Somsak Ruchirawat, Prasat Kittakoop, Barry R O'Keefe, Kirk R Gustafson

Open access · greenAbstract read
In one paragraph

Article in Magnetic resonance in chemistry : MRC, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Trong D TranMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD.
Laura K CartnerMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD.
Heidi R BokeschMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD.
Curtis J HenrichMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD.
Xin W WangLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD.
Chulabhorn MahidolChulabhorn Research Institute, Office of Research, Laboratory of Natural Products, Bangkok, Thailand.
Somsak RuchirawatChulabhorn Research Institute, Office of Research, Laboratory of Natural Products, Bangkok, Thailand.
Prasat KittakoopChulabhorn Research Institute, Office of Research, Laboratory of Natural Products, Bangkok, Thailand.
Barry R O'KeefeMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD.
Kirk R GustafsonMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD.ORCID 0000-0001-6821-4943
Leidos (United States) · USTarget (United States) · USMinistry of Public Health · THChulabhorn Graduate Institute · THNational Cancer Institute · US

Funding

Strategies for improving early detection, diagnosis and treatment of liver cancerZIABC010313 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WANG, XIN WEI · 2009 to 2025
$18.1M
Natural Products Discovery and Characterization Through Network CollaborationsZIABC011568 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI DU, LIN · 2014 to 2025
$17.2M
Assay development and screening for molecular targets and discoveryZIABC011904 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WILSON, BRICE · 2019 to 2025
$12.8M
Cell-free assay technologies for the identification of active compoundsZIABC011471 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI OKEEFE, BARRY · 2012 to 2025
$12.4M
CCR NIH HHS HHSN261200800001CIntramural NIH HHS ZIA BC011568Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer ResearchNCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

The indolocarbazole family of bisindole alkaloids is best known for the natural product staurosporine, a protein kinase C inhibitor that belongs to the indolo[2,3-a]carbazole structural class. A large number of other indolo[2,3-a]carbazoles have subsequently been isolated and identified, but other isomeric forms of indolocarbazole natural products have rarely been reported. An extract of the marine sponge Damiria sp., which represents an understudied genus, provided two novel alkaloids named damirines A (1) and B (2). Their structures were assigned by comprehensive NMR spectroscopic analyses, and for compound 2, this included application of the LR-HSQMBC pulse sequence, a long-range heteronuclear correlation experiment that has particular utility for defining proton-deficient scaffolds. The damirines represent a new hexacyclic carbon-nitrogen framework comprised of an indolo[3,2-a]carbazole fused with either an aminoimidazole or a imidazolone ring. Compound 1 showed selective cytotoxic properties toward six different cell lines in the NCI-60 cancer screen.

Indexed as

AnimalsAntineoplastic AgentsBiological ProductsCarbazolesCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorHumansIndole AlkaloidsMagnetic Resonance SpectroscopyMolecular ConformationPoriferaStereoisomerismAntineoplastic AgentsBiological ProductsCarbazolesIndole Alkaloidsstaurosporine aglyconeDamiriadamirineindolocarbazoleLR-HSQMBC

Identifiers

PMID31379005
PMCPMC7428849
OpenAlexW2965487417

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.